The Importance of 5-Aza-2'-Deoxycytidine Dose-Schedule in Cancer Treatment
Author Information
Author(s): Maryse Lemaire, Guy G Chabot, Noël JM Raynal, Louise F Momparler, Annie Hurtubise, Mark L Bernstein, Richard L Momparler
Primary Institution: Université de Montréal
Hypothesis
What is the optimal dose-schedule of 5-aza-2'-deoxycytidine for effective cancer treatment?
Conclusion
Increasing the dose of 5-aza-2'-deoxycytidine significantly enhances its antineoplastic activity in mouse models of cancer.
Supporting Evidence
- Higher concentrations of DAC led to greater loss of clonogenicity in cancer cells.
- DAC reactivated tumor suppressor genes and inhibited DNA methylation.
- Increased doses of DAC improved survival times in mice with leukemia.
Takeaway
This study found that giving more of a cancer drug called DAC helps it work better against cancer cells in mice.
Methodology
Clonogenic assays were performed on leukemic and tumor cell lines, and in vivo antineoplastic activity was evaluated in mice.
Limitations
The study primarily used mouse models, which may not fully replicate human responses.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website